Abstract P1-02-23: Deciphering VISTA immunoreceptor mechanisms to target VISTA+ triple-negative breast cancers

Joshua J. Gruber, Yan Zhao, T Andoh, Fatima Charles, Ishrat Durdana, Priyanka Reddy, Kristina Paul, Harsh Goar, Caiden J. Golder, Marisa M. Juntilla, Yan Peng, James Ford, Allison W. Kurian, Melinda L. Telli, Song Zhang, Robert West, Andrew M. Lipchik, M SnyderClinical 2025 · DOI

Abstract

Abstract Introduction: Current FDA-approved immunotherapeutics for triple-negative breast cancer (TNBC) are only available for a subset of patients, highlighting the need to develop improved immune-targeting strategies. VISTA (V-domain Ig suppressor of T cell activation) is a single-pass transmembrane immune checkpoint receptor that is an emerging clinical target for cancer immunotherapy. It is expressed widely on lymphoid and myeloid cells in healthy individuals, is commonly expressed on cells of the tumor microenvironment and can be abnormally upregulated on tumor cells in a wide variety of tumors. Although VISTA confers quiescence to naïve T cells, molecular mechanisms responsible for this effect remain unclear. Also, the effects of VISTA expression on tumor cells remains poorly defined. Results: Through cell line multi-omics profiling and histologic examination of 250 human TNBC clinical specimens we identify a subtype of TNBC with extremely high VISTA expression (∼10% of all primary tumors). These tumors had undetectable PDL1 expression, very low infiltrating tumor lymphocytes and diminished proliferative rates (Ki67 ∼50%, compared to >75% for VISTA-low tumors). We characterized VISTA-high tumor biology by expressing VISTA in TNBC cell lines and monitoring tumor growth in vivo after mammary fat pad injections. In all tested cell lines (HCC1806, MDA-MB-231, 4T1, EO771) enforced expression of VISTA significantly diminished tumor growth, which was evident in both immunocompetent and immunosuppressed hosts. Molecular investigations revealed that VISTA could decrease tumor growth through its intracellular domain, which repressed EGFR trafficking and decreased EGF-dependent cell growth. We purified proteins bound to the VISTA intracellular domain, which identified PTB-domain-containing proteins and Rab11 effector proteins as functional VISTA interactors responsible for suppressing EGFR activity. These effects were mapped to a four amino acid (NPGF) motif in the VISTA intracellular domain, which could directly bind and recruit NUMB, a PTB-domain containing protein. Mutation of the VISTA NPGF motif completely reverted binding to NUMB, repression of EGFR activity and the slow tumor growth phenotype of VISTA+ tumors in vivo. To further demonstrate the functional significance of the VISTA NPGF motif we generated mice with VISTA NPGF mutations (homozygous NPAA) and studied their T cells, which naturally express high VISTA levels. T cells from NPAA mutant mice evinced increased proliferation in response to T cell receptor stimulation compared to control, demonstrating that the NPGF motif is a bona fide repressor of cell division in both tumors and T cells. Mice bearing VISTA NPAA mutations in their immune system also had diminished tumor growth compared to WT mice when injected with TNBC cell lines. Conclusions: We report a distinct subtype of TNBC characterized by high VISTA expression, low PDL1 expression and decreased proliferative index. This work identifies mechanisms by which VISTA can diminish cell division of tumors or T cells through recruitment of effector proteins to an NPGF motif in its intracellular domain. Clinical trials of VISTA-blocking monoclonal antibodies are ongoing and may have relevance for VISTA+ TNBCs that are unlikely to respond to PD1-targeted agents. In addition, therapeutic strategies to target the VISTA intracellular domain in T cells are predicted to improve immunotherapy responses and could be considered for VISTA-negative TNBCs. Citation Format: Joshua Gruber, Yan Zhao, Tina Andoh, Fatima Charles, Ishrat Durdana, Priyanka Reddy, Kristina Paul, Harsh Goar, Caiden Golder, Marisa Juntilla, Yan Peng, James Ford, Allison Kurian, Melinda Telli, Song Zhang, Robert West, Andrew Lipchik, Michael Snyder. Deciphering VISTA immunoreceptor mechanisms to target VISTA+ triple-negative breast cancers [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-02-23.
BibTeX
@inproceedings{gruber2025abstract,
  author = {Joshua J. Gruber and Yan Zhao and T Andoh and Fatima Charles and Ishrat Durdana and Priyanka Reddy and Kristina Paul and Harsh Goar and Caiden J. Golder and Marisa M. Juntilla and Yan Peng and James Ford and Allison W. Kurian and Melinda L. Telli and Song Zhang and Robert West and Andrew M. Lipchik and M Snyder},
  title = {{Abstract P1-02-23: Deciphering VISTA immunoreceptor mechanisms to target VISTA+ triple-negative breast cancers}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p1-02-23},
}

Loading related content...

Figure